All Outputs (2)

Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID) (2021)
Journal Article
Wild, J. M., Porter, J. C., Molyneaux, P. L., George, P. M., Stewart, I., Allen, R. J., …Jenkins, R. G. (2021). Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). BMJ Open Respiratory Research, 8(1), Article e001049. https://doi.org/10.1136/bmjresp-2021-001049

Introduction The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness a... Read More about Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID).

Mast Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis (2021)
Journal Article
Babaei-Jadidi, R., Dongre, A., Miller, S., Castellanos Uribe, M., Stewart, I. D., Thompson, Z. M., …Johnson, S. R. (2021). Mast Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis. American Journal of Respiratory and Critical Care Medicine, 204(4), 431-444. https://doi.org/10.1164/rccm.202007-2854OC

Rationale: Lymphangioleiomyomatosis (LAM) is a multisystem disease that causes lung cysts and respiratory failure. Loss of TSC (tuberous sclerosis complex) gene function results in a clone of “LAM cells” with dysregulated mTOR (mechanistic target of... Read More about Mast Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis.